Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL — Stella

Home/Peripheral T Cell Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to Peripheral T Cell Lymphoma trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Shanghai General Hospital, Shanghai, Shanghai Municipality

Key details

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Enrollment target

~50 participants

Started

July 2024

Primary completion

July 2026

Age range

18 Years – 70 Years

Last updated August 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.